Patient Advocacy Group Claims Gilead Delayed Development Of Safer HIV Drug To Maximize Profits During Patent Period Of Older, Less Safe Drug

The Washington Post (12/5, Rowland) reports PrEP4All Collaboration, a patient advocacy group, “filed a petition...with the U.S. Patent and Trademark Office contending Gilead knew its new, improved drug [tenofovir alafenamide] – approved in 2015 and now pa...